Duquenne, L, Gul, H and Emery, P (2019) Safety evaluation of Adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view. Expert opinion on drug safety, 8 (1). ISSN 1474-0338
Abstract
INTRODUCTION:Immune-Mediated Inflammatory Disorders (IMIDs) are systemic conditions which arise secondary to complex immune mechanism defects and can affect many organs. While previous therapies based on steroids and immunosuppressive agents had a poor risk/benefit balance, TNFα specific inhibitors such as adalimumab have revolutionised the course of many diseases and patient outcomes. However, concerns were raised regarding the increased risk of infectious diseases and neoplasia due to potential prospective loss of immune control. This is especially true when considering that IMIDs concerns elderly/frail populations, with multiple co-morbidities, organ damage and often long-term steroid therapy. Areas covered: Now prescribed for more than 15 years for a diverse range of indications, long-term data highlighting the efficacy and safety are available and led to recommendations for the daily practice that will be discussed. Expert opinion: The efficacy of adalimumab changed the therapeutic paradigm of many diseases. Its tolerance is good and it is the most widely prescribed therapy in many IMIDs. It is now the standard of care arm in head to head trials. In the long term, adalimumab dominant role might be weakened by more targeted therapies but its varied indications among IMIDs should secure its position as an important tool in our practice for years to come.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | This is an Accepted Manuscript of an article published by Taylor & Francis in Expert opinion on drug safety on 16/11/18, available online: http://dx.doi.org/10.1080/14740338.2018.1549541 (https://authorservices.taylorandfrancis.com/sharing-your-work/) |
Keywords: | Adalimumab, Immune-Mediated Inflammatory Disorders, Drug safety, Treatment, TNF inhibitors |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 07 Dec 2018 14:20 |
Last Modified: | 16 Nov 2019 01:38 |
Status: | Published |
Publisher: | Taylor & Francis |
Identification Number: | 10.1080/14740338.2018.1549541 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:139647 |